New Agents and Therapeutic Combinations for the Frontline Treatment of Peripheral T-Cell Lymphoma

Review expert perspectives on applying the latest efficacy and safety data to first-line treatment of different PTCL subtypes using both established and investigational regimens.
person default
Helen Hancock, NP
Steven M. Horwitz, MD
Physicians: maximum of 0.6 AMA PRA Category 1 Credits
Registered Nurses: 0.6 Nursing contact hours
Physician Assistants: maximum of 0.6 hours of AAPA Category I (Preapproved) credits
Released: August 28, 2019 Expiration: August 27, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Understand how unique agent mechanisms of action can specifically target PTCL subtypes
  • Assess molecular and phenotypic biomarkers as part of the diagnosis of PTCL and individualization of therapy decisions
  • Plan frontline treatment strategies for PTCL based on available clinical data along with expert and guideline recommendations
  • Refer eligible patients with PTCL to clinical trials of new agents and strategies for frontline treatment

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Seattle Genetics

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Helen Hancock, NP

Clinical Trials Nurse Practitioner
T-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
New York, New York

Helen Hancock, NP, has no relevant conflicts of interest to report.
Steven M. Horwitz, MD

Associate Attending Physician
Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill-Cornell Medical Center
New York, New York

Steven M. Horwitz, MD, has disclosed that he has received funds for research support from ADC Therapeutics, Aileron, Celgene, Forty Seven, Infinity/Verastem, Kyowa Hakko Kirin, Millennium/Takeda, Seattle Genetics, and Trillium and consulting fees from ADC Therapeutics, Affimed, Aileron, Angimmune, BeiGene, Corvus, Forty Seven, Infinity/Verastem, Innate Pharma, Kura, Kyowa Hakko Kirin, Merck, Millennium/Takeda, miRagen, Mundipharma, Portola, Seattle Genetics, and Syros.

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, nurses, physician assistants, and other healthcare professionals who provide care for patients with peripheral T-cell lymphoma.

Goal

The goal of this activity is to improve participants’ ability to individualize frontline treatment decisions and improve outcomes for patients with peripheral T-cell lymphoma.

Accreditation

Joint Accreditation Statement

 

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.6 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.6 contact hour.

Physician Assistant Continuing Education

Credit Designation

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.6 AAPA Category 1 CME credit. Approval is valid until August 27, 2020 . PAs should only claim credit commensurate with the extent of their participation.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.6 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 28, 2019, through August 27, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Latest evidence on effective management of chronic lymphocytic leukemia (CLL) using BTK inhibitors in this video from Clinical Care Options (CCO)

Danielle Brander, MD Nicole Lamanna, MD Jeff P. Sharman, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: September 16, 2020 Expired: September 15, 2021

Nicole Lamanna, MD, on modifying CLL treatment during COVID-19 pandemic, IVIg as COVID-19 prophylaxis, and the role of BTK inhibition, from CCO

Nicole Lamanna, MD Released: September 14, 2020

On-demand Webcast featuring experts’ review of evolving strategies for optimal treatment of patients with relapsed/refractory multiple myeloma in 2020

Shaji Kumar, MD
Program Director
Natalie S. Callander, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 14, 2020 Expired: September 13, 2021

Download this slideset from a CCO Live Meeting Series to review the latest evidence on selecting optimal management strategies for follicular lymphoma

John M. Burke, MD Peter Martin, MD Released: September 11, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?